Argenx debuts first DTC for myasthenia gravis med Vyvgart even as MG community effort continues
In a quick turn to DTC, argenx is rolling out its first campaign for myasthenia gravis med Vyvgart just a month after FDA approval.
Four real MG patients star in the inaugural TV ad that, while unbranded and not mentioning Vyvgart by name, does focus on a “new FDA-approved treatment” for the debilitating autoimmune disease.
A voiceover in the 30-second commercial asks the question why do patients want a new treatment? Each patient is then featured in succession as they answer with reasons like “because we want to go out to dinner with friends” or “because in family photos, we want to be able to smile.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters